Skip to content

ImmunoCellular Therapeutics, Ltd.: 10-Q filed 2012-08-14

What ImmunoCellular Therapeutics, Ltd. reported in its quarterly report filed 2012-08-14 (fiscal Q2 2012): 29 published measures, 109 facts as tagged in accession 0001193125-12-352981.

This filing

Form
10-Q (quarterly report)
Filed
2012-08-14
Fiscal period
fiscal Q2 2012
Accession
0001193125-12-352981 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All ImmunoCellular Therapeutics, Ltd. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2012-06-3012,064,413USD
At 2011-12-317,150,757USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2012-06-302,343,743USD
At 2011-12-313,232,060USD
At 2010-12-312,335,830USD
At 2009-12-311,096,995USD
At 2008-12-312,940,336USD
At 2007-12-314,997,709USD
At 2006-12-31189,662USD
At 2005-12-3120,262USD
At 2004-12-31-11,494USD
At 2004-02-2497USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2012-06-3011,339,843USD
At 2011-12-316,653,168USD
At 2011-06-3010,147,636USD
At 2010-12-315,319,776USD
At 2004-02-240USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2012-04-01 to 2012-06-30-6,451,817USD91
2012-01-01 to 2012-06-30-14,341,252USD182
2004-02-25 to 2012-06-30-40,922,443USD3049
2011-01-01 to 2011-12-31-5,719,903USD365
2011-04-01 to 2011-06-30-1,550,825USD91
2011-01-01 to 2011-06-30-4,309,096USD181
2010-01-01 to 2010-12-31-6,150,142USD365
2009-01-01 to 2009-12-31-2,626,205USD365
2008-01-01 to 2008-12-31-3,059,730USD366
2007-01-01 to 2007-12-31-3,614,753USD365
2006-01-01 to 2006-12-31-5,152,713USD365
2005-01-01 to 2005-12-31-246,004USD365
2004-02-25 to 2004-12-31-11,741USD311

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2012-01-01 to 2012-06-30-6,889,220USD182
2004-02-25 to 2012-06-30-23,053,181USD3049
2011-01-01 to 2011-06-30-2,810,041USD181

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2012-01-01 to 2012-06-305,668USD182
2004-02-25 to 2012-06-30151,532USD3049
2011-01-01 to 2011-06-3037,925USD181

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2012-04-01 to 2012-06-300USD91
2012-01-01 to 2012-06-300USD182
2004-02-25 to 2012-06-30300,000USD3049
2011-04-01 to 2011-06-300USD91
2011-01-01 to 2011-06-300USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2012-01-01 to 2012-06-3011,581,563USD182
2004-02-25 to 2012-06-3034,569,556USD3049
2011-01-01 to 2011-06-307,675,826USD181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2012-01-01 to 2012-06-30-5,668USD182
2004-02-25 to 2012-06-30-176,532USD3049
2011-01-01 to 2011-06-30-37,925USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2012-06-30-43,014,943USD
At 2011-12-31-28,673,691USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2012-04-01 to 2012-06-300USD91
2012-01-01 to 2012-06-300USD182
2004-02-25 to 2012-06-300USD3049
2011-04-01 to 2011-06-300USD91
2011-01-01 to 2011-06-300USD181

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2012-06-3095,064USD
At 2011-12-3176,402USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2012-01-01 to 2012-06-30348,724USD182
2004-02-25 to 2012-06-308,506,573USD3049
2011-01-01 to 2011-06-30633,839USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2012-04-01 to 2012-06-30-3,130,572USD91
2012-01-01 to 2012-06-30-6,180,013USD182
2004-02-25 to 2012-06-30-33,714,354USD3049
2011-04-01 to 2011-06-30-1,829,930USD91
2011-01-01 to 2011-06-30-3,542,846USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2012-06-3011,957,929USD
At 2011-12-316,744,454USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2012-06-301,021,663USD
At 2011-12-311,761,289USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2012-06-30573,675USD
At 2011-12-311,316,540USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2012-04-01 to 2012-06-302,189,633USD91
2012-01-01 to 2012-06-304,188,169USD182
2004-02-25 to 2012-06-3014,737,048USD3049
2011-04-01 to 2011-06-30858,183USD91
2011-01-01 to 2011-06-301,775,397USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2012-06-3040,411,792shares
At 2011-12-3128,613,984shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2012-06-3045,354,645USD
At 2011-12-3131,902,890USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2012-06-30147,414USD
At 2011-12-31105,864USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2012-06-3052,350USD
At 2011-12-3129,462USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2012-06-30447,988USD
At 2011-12-31444,749USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2012-04-01 to 2012-06-30-6,451,817USD91
2012-01-01 to 2012-06-30-14,341,252USD182
2004-02-25 to 2012-06-30-43,014,943USD3049
2011-04-01 to 2011-06-30-1,550,825USD91
2011-01-01 to 2011-06-30-4,309,096USD181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2012-04-01 to 2012-06-30837,322USD91
2012-01-01 to 2012-06-301,643,120USD182
2004-02-25 to 2012-06-3010,634,600USD3049
2011-04-01 to 2011-06-30579,889USD91
2011-01-01 to 2011-06-301,133,610USD181

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2012-04-01 to 2012-06-3011,444USD91
2012-01-01 to 2012-06-3022,888USD182
2004-02-25 to 2012-06-3052,350USD3049
2011-04-01 to 2011-06-303,603USD91
2011-01-01 to 2011-06-308,016USD181

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2012-01-01 to 2012-06-3022,888USD182
2004-02-25 to 2012-06-3052,350USD3049
2011-01-01 to 2011-06-308,016USD181

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2012-01-01 to 2012-06-300USD182
2004-02-25 to 2012-06-30125,247USD3049
2011-01-01 to 2011-06-300USD181

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2012-01-01 to 2012-06-30-560,266USD182
2004-02-25 to 2012-06-30573,325USD3049
2011-01-01 to 2011-06-30-108,414USD181

Inspect the source

Entity
ImmunoCellular Therapeutics, Ltd. / CIK 0000822411
Captured
SEC response SHA-256
0eba79ec53d6fb769bdb10da640228441bb5660977a2ac000a6d3fe9f3678be8

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000822411.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))